Multiple Myeloma
Multiple Myeloma (MM) is a cancer that forms in a type of white blood cell called plasma cells, leading to the production of abnormal proteins that can cause various health issues, including bone pain and anemia.
Multiple Myeloma: ABBV-453 Treatment Study
We are studying the safety and effects of ABBV-453, alone or with other treatments, for adults with multiple myeloma. This research aims to understand how well it works and how it is tolerated by patients.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have a documented diagnosis of multiple myeloma (MM)?
- Do you have measurable disease with serum M-protein of 0.5 g/dL or higher, urine M-protein of 200 mg or more in 24 hours, or serum free light chain of 10 mg/dL or more?
- Have you had any major surgery in the past 4 weeks?
- Have you had a recent infection that required treatment within the last 7 days?
- Are you currently receiving any treatment for B-cell lymphoma (BCL)-2 inhibitors?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Surzetoclax
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Hematology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Hematology
Ledeberg, Belgium
Centre hospitalier universitaire de Liege
Hematology
Tilff, Belgium
Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.